RecruitingPhase 1Phase 2NCT06949904

The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia


Sponsor

Mian Muhammad Hassan Ahmed

Enrollment

60 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone. The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone. The control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.


Eligibility

Min Age: 1 MonthMax Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Melatonin for people with pneumonia childhood. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMelatonin

1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days


Locations(1)

Pakistan Institute of Medical Sciences

Islamabad, Islamabad, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06949904


Related Trials